Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy PT assessment: 1) Speech has improved. Now he is abl...

By: neurogenbsi

Follow this link:
Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India. - Video

Recommendation and review posted by Bethany Smith

Stem cell therapy for AVN in India, Experience of patient from Canada
Avascular necrosis also known as osteonecrosis, aseptic necrosis, and ischemic bone necrosis. It is a disease resulting from the temporary or permanent loss ...

By: StemRx BioScience

Read more here:
Stem cell therapy for AVN in India, Experience of patient from Canada - Video

Recommendation and review posted by Bethany Smith

China Rises
What are they teaching our children - Capitalism is bad and Communism is good? According to this parent that #39;s exactly right!

By: K. Michael Card

Visit link:
China Rises - Video

Recommendation and review posted by Bethany Smith

MONDAY, April 1 (HealthDay News) -- The benefits of genetic testing to assess the risk of breast and ovarian cancers linked to the BRCA gene are limited to a small number of women, a new report indicates.

Mutations in the BRCA1 and BRCA2 genes greatly increase a woman's risk of developing these cancers. Women with these mutations have a 70 percent chance of developing breast cancer -- which is five times greater than in the general population -- and increase their lifetime risk of ovarian cancer from less than 2 percent to as high as 46 percent.

An important step in preventing these cancers is helping women understand their risk, according to the U.S. Preventive Services Task Force.

In preparing a draft report and recommendations, the task force examined available evidence to determine if genetic counseling and testing could benefit women most likely to have BRCA mutations.

The task force concluded that more than 90 percent of American women -- those whose family history does not indicate an increased risk for BRCA1 or BRCA2 mutations -- will not benefit from genetic testing or counseling.

This is because current tests often provide inconclusive results and these women could be burdened with the uncertainty of whether they are at increased risk for cancer. Many of these women might choose to take powerful medications or have major surgery to reduce their risk of cancer, which would be unnecessary if they were not at increased risk.

Therefore, the task force said it continues to recommend against genetic counseling and BRCA testing in these women.

"At this point, scientific evidence only shows that BRCA1 and BRCA2 testing is beneficial for women who have reviewed their family history of breast or ovarian cancer with a primary-care professional and discussed the pros and cons of the screening test with a trained genetic counselor," task force chairwoman Dr. Virginia Moyer said in task force news release.

"We hope that further research into ways to use genomic science, such as identifying women who have harmful BRCA genes but do not have a family history of cancer, could improve screening practices and even prevent some cancers," she added.

The task force said it also found evidence to recommend that primary-care health providers screen women who have family members with breast or ovarian cancer to determine if their family history is associated with an increased possibility of having BRCA1 or BRCA2 mutations.

Continue reading here:
Breast Cancer Gene Tests Won't Help Most Women: Report

Recommendation and review posted by Bethany Smith

CLARENCE, N.Y.--(BUSINESS WIRE)--

22nd Century Group, Inc. (OTCBB: XXII), a company that has developed groundbreaking technology for tobacco harm reduction products, today announced that the United States Patent and Trademark Office (US PTO) has issued Patent No. 8,410,341 for the N-methylputrescine oxidase (MPO) gene technology. MPO is essential for production of nicotine in the tobacco plant. As previously announced, the US PTO issued a Notice of Allowance on December 24, 2012 for this technology; however, yesterdays issuance marks the official grant of the patent.

The allowed claims of Patent No. 8,410,341, entitled, NUCLEIC ACID ENCODING N-METHYLPUTRESCINE OXIDASE AND USES THEREOF, cover nucleic acids encoding MPO, methods for producing tobacco plants with either reduced or increased nicotine levels and tobacco plants produced by the foregoing. The US PTO granted Patent No. 8,410,341 on April 2, 2013 to the National Research Council Canada (NRC). 22nd Century is NRCs exclusive worldwide licensee of MPO and other technologies.

Patent No. 8,410,341 is the first MPO gene patent issued anywhere in the world. Including the patent term adjustment, this U.S. patent will expire in December 2027. Patent Application PCT/IB2007/003550 is the related international application to U.S. Patent No. 8,410,341. Additional MPO patent applications are pending in the U.S., Canada and China.

The MPO gene encodes a protein involved in a key step of nicotine biosynthesis. Scientists have attempted to clone the MPO gene for decades. MPO expression can be either down-regulated or up-regulated to produce tobacco plant varieties and tobacco products with a wide range of nicotine levels (from very low to high), or altered ratios of nicotine and other nicotinic alkaloids such as anatabine and nornicotine. Dr. Jonathon Page and Enwu Liu of the NRC Plant Biotechnology Institute are the inventors of the MPO technology. 22nd Century funded subject patent and research and development expenses at NRC from 2006 to 2008.

The MPO gene technology is one of several 22nd Century patent families representing the companys second-generation gene technology for modifying the content of nicotine and other nicotinic alkaloids in the tobacco plant. 22nd Centurys vice president of research and development, Dr. Michael Moynihan stated, We are very pleased that the US PTO has granted the MPO patent. Our second-generation technology has significant advantages over our first generation technology.

22nd Centurys patent portfolio consists of 15 issued U.S. patents and 9 pending U.S. patent applications. Globally, 22nd Century owns or is the exclusive licensee of 109 issued patents in 78 countries plus an additional 39 pending patent applications mainly related to all of the key nicotine biosynthesis genes and transcription factors and tobacco harm reduction products produced therefrom.

For additional information, please visit: http://www.xxiicentury.com

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release. The words may, would, will, expect, estimate, anticipate, believe, intend and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2012, filed on March 18, 2013, including the section entitled Risk Factors, and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.

Read this article:
22nd Century Group Announces U.S. Patent Issues for MPO Nicotine Biosynthesis Gene

Recommendation and review posted by Bethany Smith

GCSE History Revision 2
A song to help GCSE students revise material about Hitler and the Nazi State.

By: Rick Rogers

Read more:
GCSE History Revision 2 - Video

Recommendation and review posted by Bethany Smith

Genetically Evolved Technology: Luke Bawazer at TEDxWarwick
Luke Bawazer works in Fiona Meldrum #39;s laboratory at University of Leeds, where he conducts research at the interface of chemistry, materials science, and syn...

By: TEDxTalks

Read more here:
Genetically Evolved Technology: Luke Bawazer at TEDxWarwick - Video

Recommendation and review posted by Bethany Smith

Mixing Human DNA Genetic engineering

By: SearchTheLord

The rest is here:
Mixing Human DNA Genetic engineering - Video

Recommendation and review posted by Bethany Smith

Mark of the beast, the work of fallen angels.
like or dislike the video please.

By: Jared McGee

More here:
Mark of the beast, the work of fallen angels. - Video

Recommendation and review posted by Bethany Smith

Public release date: 2-Apr-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, April 2, 2013The seizures that affect people with temporal-lobe epilepsy usually start in a region of the brain called the hippocampus. But they are often able to involve other areas outside the temporal lobe, propagating via anatomically and functionally connected networks in the brain. New research findings that link decreased brain cell concentration to altered functional connectivity in temporal-lobe epilepsy are reported in an article in Brain Connectivity, a bimonthly peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Brain Connectivity website at http://www.liebertpub.com/brain.

Martha Holmes and colleagues from Vanderbilt University, Nashville, TN, identified regions in the brains of patients with temporal-lobe epilepsy that had reduced gray-matter concentrations. Greater reductions in gray-matter concentration correlated with either decreased or increased signaling and communication between brain regions connected through known functional networks.

The authors present their findings in the article "Functional Networks in Temporal-Lobe Epilepsy: A Voxel-Wise Study of Resting-State Functional Connectivity and Gray-Matter Concentration."

"This is one of the first studies to actually correlate both functional and structural brain changes in epilepsy," says Christopher Pawela, PhD, Co-Editor-in-Chief and Assistant Professor, Medical College of Wisconsin. "This is an exciting finding and may have impact in other brain disorders in which both the structure and function of the brain are involved."

###

About the Journal

Brain Connectivity is the journal of record for researchers and clinicians interested in all aspects of brain connectivity. The Journal is under the leadership of Founding and Co-Editors-in-Chief Christopher Pawela, PhD and Bharat Biswal, PhD, Associate Professor, University of Medicine and Dentistry of New Jersey. It includes original peer-reviewed papers, review articles, point-counterpoint discussions on controversies in the field, and a product/technology review section. To ensure that scientific findings are rapidly disseminated, articles are published Instant Online within 72 hours of acceptance, with fully typeset, fast-track publication within four weeks. Tables of content and a sample issue can be viewed on the Brain Connectivity website at http://www.liebertpub.com.

About the Publisher

The rest is here:
Epileptic seizures can propagate using functional brain networks

Recommendation and review posted by Bethany Smith

Apr. 2, 2013 A paper published this month in the medical journal The Lancet Neurology suggests that a broad spectrum of developmental and psychiatric disorders, ranging from autism and intellectual disability to schizophrenia, should be conceptualized as different manifestations of a common underlying denominator, "developmental brain dysfunction," rather than completely independent conditions with distinct causes.

In "Developmental Brain Dysfunction: Revival and Expansion of Old Concepts Based on New Genetic Evidence," the authors make two key points:

Developmental disorders (such as autism and intellectual disability) and psychiatric disorders (such as schizophrenia and bipolar disorder), while considered clinically distinct, actually share many of the same underlying genetic causes. This is an example of "variable expressivity:" the same genetic variant results in different clinical signs and symptoms in different individuals. When quantitative measures of neuropsychological and neurobehavioral traits are studied instead of categorical diagnoses (which are either present or absent) and individuals are compared to their unaffected family members, it is possible to more accurately demonstrate the impact of genetic variants.

According to Andres Moreno De Luca, M.D., research scientist at the Autism and Developmental Medicine Institute at Geisinger Health System and article co-author, "Recent genetic studies conducted in thousands of individuals have shown that identical genetic mutations are shared among neurodevelopmental disorders that are thought to be clinically distinct. What we have seen over the past few years is that genetic mutations that were initially found in individuals with one disorder, such as intellectual disability or autism, are then identified in people with an apparently different condition like schizophrenia, epilepsy, or bipolar disorder."

"It turns out that the genes don't respect our diagnostic classification boundaries, but that really isn't surprising given the overlapping symptoms and frequent co-existence of neurodevelopmental disorders," said Scott M. Myers, M.D., autism specialist at Geisinger Health System and article co-author.

"We believe this study supports use of the term 'developmental brain dysfunction' or DBD, which would encompass the broad spectrum of neurodevelopmental and neuropsychiatric disorders," said David H. Ledbetter, Ph.D., executive vice president and chief scientific officer at Geisinger Health System, and article co-author. "Additionally, it is clear that diagnostic tools such as whole genome analysis for both children and their families are essential when diagnosing and treating these disorders in order to ensure the most personalized treatment."

An example used in the study was analysis of intelligence quotient (IQ) scores. The average IQ score in the general population is 100. Historically, the medical community has defined intellectual disability as an IQ of less than 70 (with concurrent deficits in adaptive functioning). But according to Dr. Ledbetter, there is little difference in the function of a child with an IQ of 69 versus 71, yet one may be diagnosed with a disability and the other may not.

"We know a variety of factors contribute to IQ score, including genetics, as a child's IQ is highly correlated with that of his or her parents and siblings. Therefore, an important factor to take into consideration when interpreting IQ is family background," said Dr. Ledbetter. "Imagine if we have a child with a genetic abnormality, but the child's IQ is 85. Technically, we would not diagnose this child with a disability. However, if the family of this child has IQs around 130, we could consider that this child's genetic anomaly has 'cost' him or her 45 IQ points -- a very substantial difference."

According to Dr. Myers, "One implication of this concept is that studies designed to investigate the causes and mechanisms of developmental brain dysfunction should focus on measurement of quantifiable neuropsychological and neurobehavioral traits across groups of individuals with different clinical diagnoses. Another is that whenever possible, individuals with a particular genetic variant or other risk factor should be compared to their unaffected family members, not just to population norms."

Other authors on the paper were Thomas Challman, M.D. of Geisinger; Daniel Moreno De Luca, M.D., of Yale University, New Haven, Conn.; and David Evans, Ph.D., of Bucknell University, Lewisburg, Pa.

Read more here:
New genetic evidence suggests a continuum among neurodevelopmental and psychiatric disorders

Recommendation and review posted by Bethany Smith

Gene Therapy: Repairing our DNA -- February 21, 2013
The idea of gene therapy mdash;replacing a damaged gene with a working copy mdash;has been around for a long time, but with only modest success. But that has all changed...

By: HutchinsonCenter1

Continue reading here:
Gene Therapy: Repairing our DNA -- February 21, 2013 - Video

Recommendation and review posted by Bethany Smith

Breakthrough cancer research studies DNA
Scientists say they have found dozens of DNA markers that could help predict a person #39;s risk of developing certain types of cancer. It means tests could be u...

By: AlJazeeraEnglish

See the rest here:
Breakthrough cancer research studies DNA - Video

Recommendation and review posted by Bethany Smith

SP1202 Draft - Gene Therapy
All pictures and music credits go to their respective owners!

By: jjtoh89

Go here to see the original:
SP1202 Draft - Gene Therapy - Video

Recommendation and review posted by Bethany Smith

London, UK - Fertility regulators in the UK have paved the way for the introduction of a radical form of gene therapy in which babies are created using cellular material from three people.

The Human Fertilisation and Embryology Authority (HFEA) advised the government recently that there is no evidence "mitochondrial replacement" - an advanced form of in-vitro fertilisation - is unsafe, and ministers will now decide whether to proceed with the technique.

Critics say the move is the first step on a slippery slope towards the creation of "designer babies" built to order that heralds a new era of "consumer eugenics" - with potentially disastrous implications for humankind.

"There has been a consensus for some time in about 50 or 60 countries that we should not manipulate the human 'germline' - that is, the cells that give rise to a new individual," saidDr David King, director of the group Human Genetics Alert.

"This is the first time that there has been official approval for crossing that line and, once you cross the Rubicon, it becomes difficult not to move to the next stage - full-fledged enhancement, genetic engineering."

Mitochondria are cigar-shaped components of body cells that provide them with energy. If they are defective, it can starve the body of energy, leading to muscle weakness, blindness, deafness, epilepsy, heart failure, early dementia and even death.

Some form of mitochondrial disease affects about one in 200 children born each year - or a few dozen babies in Britain.

The proposed therapy targets women who harbour harmful mitochondrial DNA mutations, but who want to have their own genetic offspring instead of relying on a donated egg.

The treatment would take a donated egg cell then remove its nucleus and chromosomes containing the genetic information, but retain its healthy mitochondria. The nucleus from the egg of an affected mother would be inserted into it - either before or after fertilisation - and the fertilised egg would then be implanted in the mother's womb.

A baby born as a result should be free of the mother's mitochondrial defects - and that child's own eventual offspring should also be free of these, changing the genetic line for ever.

Link:
New gene therapy births 'designer baby' fears

Recommendation and review posted by Bethany Smith

Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Could stand with calipers and wal...

By: neurogenbsi

More here:
Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video

Recommendation and review posted by simmons

C6 Spinal Cord Injury Patient Dunking in to the pool

By: allusv

View post:
C6 Spinal Cord Injury Patient Dunking in to the pool - Video

Recommendation and review posted by sam

Apr. 2, 2013 Leukemia patients receive a bone marrow transplant, which allows them to build a "new" immune system. However, this immune system not only attacks cancer cells but healthy tissue too. Special antibodies will be used to protect healthy tissue in future.

Not too long ago, leukemia left us with no chance. Today doctors can give patients hope by transplanting bone marrow, the starting point of a "new" immune system. These transplanted cells replace the diseased, blood-building stem cells in the bone marrow and take over their job of producing healthy blood cells, while also destroying leukemia cells. The problem is that this immune system originates from a foreign body and therefore can also attack healthy tissue in the patient. The skin, liver, and intestine are most affected by these attacks -- their cells can be destroyed and the organs damaged, sometimes so severely as to cause organ failure. The medical term for this phenomenon is graft-versus-host disease (GvHD), and the scale of the problem posed by this misdirected immune response is illustrated by statistics revealing that up to 50 percent of all patients ultimately suffer from GvHD-induced damage; in up to 20 percent of cases this damage is fatal. Not to ignore the further risk: that one in five leukemia patients suffer a relapse after the transplant.

In order to combat the cancer effectively, doctors give leukemia patients chemotherapy and radiation therapy before the transplant. These treatments destroy the patient's entire blood-building system, creating space for the donor's healthy cells. Any cancer cells that might survive this treatment are identified and destroyed by the new immune cells. So that the "foreign" immune system does not turn against healthy tissue, doctors additionally give patients immunosuppressants to artificially suppress the immune system. There is a fine balance to be struck here, as immunosuppressants not only inhibit GvHD but also the desired immune response, i.e. killing off the cancer cells.

Minimizing the risk of a misdirected immune reaction

Researchers at the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig are investigating how to improve the situation for leukemia sufferers. "Our goal is to avoid GvHD without changing how the new immune effect acts on the tumor," says Dr. Stephan Fricke, head of the Immune Tolerance unit at the IZI and doctor at the Department of Hematology and Oncology, University Hospital Leipzig. "Our hopes are pinned on monoclonal antibodies, which specifically bind to the surface of immune cells and prevent the immune cells reacting adversely with the patient's tissue." It's particularly important that the antibodies also act on the blood stem cells to be transplanted and on all immune cells that develop from them. This allows researchers to modulate the cells in advance of transplantation, causing them to "tolerate" the patient's healthy tissue instead of attacking it. "We're then able to effectively reduce the risk of a GvHD without any side effects," explains Fricke. The antibodies do not alter the immune response against remaining cancer cells -- they are still destroyed as before. This reduces the risk of leukemia coming back after the transplant.

IZI scientists are currently collaborating with their colleagues from the Translational Centre for Regenerative Medicine at the Universitt Leipzig on research into the cellular foundations of these effects. What is the optimum point at which to add the antibodies to the donor bone marrow? How many antibodies should be used? Setting out to answer these questions, researchers first simulate both GvHD and the human immune system using a variety of established models. They can then determine all relevant parameters based on the simulations.

The researchers have already provided proof of principle, i.e. they were able to demonstrate that the therapy works. Now initial tests are underway on mice with a human immune system. The scientists hope that a clinical study can begin before the year is out.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

Read more from the original source:
Promising stem cell therapy for leukemia patients

Recommendation and review posted by Bethany Smith

ARAD, Israel, April 2, 2013 /PRNewswire/ --

Andain Inc. (ANDN) ("Andain" or the "Company"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields through its incubator program, today discussed and provided an update on its breakthrough, innovative stem cell therapy for treating and regenerating severely damaged muscle tissue.

Andain's innovative stem cell therapy technology rehabilitates and heals damaged muscle tissue by initiating regenerative myogenic cells (cardiac muscle), as well as striated muscle cells (skeletal muscle) growth in damaged tissue sites such as the myocardium (cardiac muscle) following an myocardial infarction (heart attack), limb pressure ulcers, and degenerative muscular diseases. The short term application is directed towards the treatment of patients with peripheral vascular disease, while the long term application is focused on the healing and regeneration of cardiac muscle following acute myocardial infarction or chronic heart failure.

Employing a patient's own cells (autologic transplantation), the Company's unique technology and process diverts the patient's own cells into specific targeted myogenic cells, which can then be inserted into the damaged tissue and accelerates the healing process. The administered myogenic or skeletal stem cells work as a network, acting in exactly the same way that the cells of skeletal and heart muscle tissue perform, and actually replenish the existing cells, thus strengthening the intended injured site following the transplantation process. This process can be utilized for different clinical pathologies as mentioned above and can also be utilized for patient using different donor as the source of the stem cells.

Our developed technology and protocols results in a promising safe regenerative therapy, without side effects, tissue rejection or the requirement of suppressive immunological treatment or malignant tumor hazard. Our technology also provides a simple, fast and safe treatment, overcoming technological difficulties associated with using other stem cell therapies sources such as embryonic, placenta, or umbilical cord blood cells that require cryogenic storage.

Andain's President and CEO Sam Elimelech, commented, "The field of stem cell therapeutics is in its early stages of growth as companies and researchers continue to uncover the vast potential and promising uses for them in the treatment and prevention of countless tissue injuries and diseases. We are in an excellent position to capitalize on the emergence of this new market. It is our belief that Orcell's cutting-edge technology and process is unique in regard to the fact that it allows for the safe and efficient directing of the patients own cells as into myogenic cells or striated muscle cells, thus eliminating the hazards associated with rejection and malignant tumors. Via our industrial incubator platform and expert scientific team, we look forward to helping Orcell commence their clinical trials later this year and make considerable progress of their technology and process closer to market."

Andain's incubator platform is currently undergoing with its stem cell technology a build-up of GLP (Good Laboratory Practice) production line as a preparation for the FDA approval stage with clinical trials scheduled for Q1 2014 at one of the foremost Heart centers in Israel under the direction of Professor Mickey Scheinowitz, one of Israel's leading scientists who gained vast experience in the understanding and treating of cardiovascular diseases.

ABOUT ANDAIN INC

Established in 2004 as a Nevada corporation with locations in Israel and the US, Andain (OTC: ANDN) commercializes novel technologies in the biotech, medical and life sciences fields, specializing in identifying technical innovations and providing a unique incubator/accelerator development and industrial platform. The company also offers technical know-how and business strategy expertise to commercialize new technologies and deliver shareholder value. For more information, please visit our website at http://www.andaininc.com.

FORWARD LOOKING STATEMENTS

See original here:
Andain Inc. Discusses and Provides Update on its Breakthrough Stem Cell Therapy for the Treatment and Regeneration of ...

Recommendation and review posted by Bethany Smith

The definition of the word gene has evolved as our knowledge has advanced. Credit: Katy.Tresedder

There's a very confusing exchange in Lewis Carroll's Through the Looking Glass: "When I use a word," Humpty Dumpty said, in rather a scornful tone, "it means just what I choose it to meanneither more nor less."

When people use the word "gene" it's also important to know what they intend it to mean. The meaning may depend on whether one is talking about carrying a gene, expressing a gene, transferring a gene or discussing how many genes we have.

One reason the definition is so confusing is that the term was coined in 1909, before we really knew what a gene was. And the effects of genes inherited characteristics were observed before we understood genes.

As our knowledge has advanced, the definition of the word gene has evolved; and with all the information from the new ENCODE project, the definition needs updating again. For an excellent academic summary of the current definition see the recent paper and poster in the journal Genome Research.

The molecular basis of inheritance

The Austrian monk Gregor Mendel carried out the first genetics in the 1860s and showed that characteristics were inherited.

We have always known that pea seeds grow into pea plants, not into kangaroos. What's more, plants with red flowers usually have offspring that have red flowers: children resemble their parents.

Mendel showed that crossing a red pea with a white pea could give rise to peas that were not pink but were either white or red.

We miss this point sometimes because we all have features from our two parents, and many features seem to blend. But Mendel showed that distinct characteristics could be inherited intact and we can think of these as each being encoded by a gene.

Go here to see the original:
Explainer: What is a gene ?

Recommendation and review posted by Bethany Smith

1 out of 4 women infected with the herpes virus suffer from memory problems. polyDNAs herpes remedy, Gene-Eden-VIR, helps immune system kill HSV-1, and therefore may be effective in treating memory problems.

Rochester, NY (PRWEB) April 01, 2013

This is even more noteworthy since 60 percent of U.S. men and women between the ages of 14 and 49 carry the herpes simplex type 1 virus. [2]

Cinnamon is a natural antiviral. [3] Moreover, cinnamon has also been found to naturally boost memory and other cognitive functions by inhibiting tau aggregation and filament formation, which are hallmarks of Alzheimer's disease (AD). [4]

Gene-Eden-VIRs all natural ingredients include cinnamon. In fact, Gene-Eden-VIR contains five all natural antiviral ingredients including cinnamon, selenium, quercetin, and licorice extract.

Mike Evans from polyDNA said The fact that nature has given us an all natural ingredient that has scientifically been shown to combat both herpes as well as prevent other cognitive problems is amazing. Its even more amazing since herpes can also cause brain problems. When we developed Gene-Eden-VIR, we knew we wanted it to be a natural remedy with as broad an application as possible. This research shows exactly how Gene Eden can take on two seemingly unrelated illnesses, focus on the source of those illnesses, and then work to combat those illnesses origin.

The public should be aware of the relationship between herpes and cognitive problems and take steps to prevent those problems from arising. polyDNA recommends boosting the immune system against a latent herpes infection through the use the all natural herpes remedy, Gene-Eden-VIR.

A recent post marketing clinical study showed that Gene-Eden-VIR is effective against the latent herpes virus. By helping the body's immune system target the latent herpes virus, people also lower their risk of developing fever blisters, cold sores, or genital herpes symptoms. [5]

Gene-Eden-VIR is highly effective against the latent herpes virus, each ingredient was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent forms of both HSV-1 and HSV-2. [6]

To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com.

Visit link:
Herpes Remedy, Gene -Eden-VIR, Can Be Effective Against Herpes Related Memory Problems

Recommendation and review posted by Bethany Smith

COSTA MESA, Calif., April 1, 2013 /PRNewswire/ --Emulex Corporation (ELX) today announced that Gene Frantz and Greg Clark have been appointed to the Emulex Board of Directors. Mr. Frantz and Mr. Clark add expertise across the spectrum of technology and telecom sectors.

(Logo: http://photos.prnewswire.com/prnh/20120403/NE81278LOGO)

"I have known Gene Frantz for several years and admired his demonstrated abilities and knowledge of the IT marketplace. I have also more recently come to know Greg Clark and I have been very impressed with his executive experience and insights concerning the network performance management market which Emulex is just entering. I believe that the Board has made excellent choices," said Jim McCluney, chief executive officer (CEO), Emulex, "and on behalf of the Board, we welcome both to the team."

Mr. Frantz is a business executive with deep technology and telecom experience. He was most recently a partner of TPG Capital ("TPG") having worked there from 1999 to 2012. Prior to joining TPG, Mr. Frantz worked at Oracle Corporation and Morgan Stanley. Mr. Frantz previously served on the boards of directors of ALLTEL, Avaya, Freescale Semiconductor, Network General, MEMC Electronic Materials, Paradyne Networks (acquired by Zhone Technologies), SMART Modular Technologies, Inc., and Certance Holdings (formerly a division of Seagate Technology acquired by Quantum Corp.). Mr. Frantz received an M.B.A. from Stanford Graduate School of Business and a B.S. in Business Administration from the University of California, Berkeley.

Mr. Clark has more than 23 years of leadership experience successfully growing technology companies through innovation, focus and execution. He has a strong operations and technology background that spans security, cloud services, supply chain and network management. Mr. Clark has been CEO and member of the Board of Directors of Blue Coat Systems, Inc. (BCSI) since August 2011. During his tenure Mr. Clark led the company through take-private transaction and associated restructuring. Under Mr. Clark's leadership BCSI has returned to double digit revenue growth with industry leading margins. Prior to joining Blue Coat, Mr. Clark was President and CEO of Mincom, a global software and services provider to asset-intensive industries. At Mincom, he expanded the company's market opportunity and revenue via the addition of cloud-based solutions and a modernization of Mincom's legacy products. The company was acquired by the ABB Group in July 2011. Before joining Mincom, Mr. Clark served as President and Chief Executive Officer at E2open, a leader in supply chain networks. Mr. Clark was one of E2open's founders and transformed E2Open from an early startup into a market-leading solutions provider supporting more than 15,000 customers worldwide. Earlier in his career, Mr. Clark founded security software firm Dascom. In 1999, IBM acquired the company, and the technology became the foundation for Tivoli's security product line. At IBM, Mr. Clark was a Distinguished Engineer and Vice President of IBM's Tivoli Systems, where he was instrumental in defining and selling IBM security and management products. He previously held senior roles with global IT companies, such as AT&T Unix Software Operation and Unix System Labs. Mr Clark serves as an independent director at the Global Healthcare Exchange (GHX).

"I am honored to be asked to join the Emulex Board," said Gene Frantz. "I look forward to working with the rest of the Board to help Emulex to realize its potential for stockholders as a leader in the connectivity and network communications markets."

"Joining the Emulex Board is an exciting opportunity for me," said Greg Clark. "The management and Board of Emulex have set an ambitious path, and I am happy to contribute my expertise for the benefit of the company and its shareholders."

"We are very pleased to have worked collaboratively with Emulex to add Gene Frantz and Greg Clark to its Board," said Jesse Cohn, a Portfolio Manager at Elliott Management, which manages funds that together are the largest shareholder of Emulex. Mr. Cohn continued, "Jim and his team at Emulex have a solid strategy and have developed leading technology in their focused markets and we believe that the addition of Gene and Greg to the Board will help Emulex to realize meaningful value for stockholders."

Emulex collaborated with Elliott in the addition of Mr. Eugene J. Frantz and Mr. Gregory S. Clark to the Emulex Corporation Board of Directors. The agreement, which includes limitations on acquisitions of additional Emulex shares by Elliott, is being filed with the SEC by Emulex.

To learn more about Emulex, please visit: http://www.emulex.com

Go here to see the original:
Emulex Appoints Gene Frantz and Greg Clark to its Board of Directors

Recommendation and review posted by Bethany Smith

RT catches the eye of The Colbert Report
On Tuesday, we reported how lawmakers at the Tennessee State Capitol were concerned about a particular sink that was thought to be a Muslim foot bath. The al...

By: RTAmerica

See the rest here:
RT catches the eye of The Colbert Report - Video

Recommendation and review posted by Bethany Smith

United States of Monsanto: GMO giant is now litigation proof
After President Obama signed the Agriculture Appropriations Bill into law on Tuesday, hundreds of thousands of people have voiced their opposition to H.R. 93...

By: RTAmerica

Read more:
United States of Monsanto: GMO giant is now litigation proof - Video

Recommendation and review posted by Bethany Smith

When is a fish not a fish but a drug? When government regulators take old laws and twist themselves into knots trying to apply them to new technology.

In the emotionally charged battle over the safety and appropriateness of genetically modified foods, people on both sides agree that the way the government oversees genetically modified plants and animals is patchy, inconsistent and at times just plain bizarre.

Soon, analysts say, the system may be stretched to the breaking point. That could leave many genetically modified crops unregulated a worry for those who fear environmental and safety risks or who believe that government vetting is key for broad public acceptance.

Its a bit of a mess, said science policy expert Jennifer Kuzma of the University of Minnesota.

The web of regulations used to govern genetically engineered species draws on more than 10 laws, all written for other purposes. Some were crafted to address issues such as tainted drugs, wheat spiked with sawdust and pollution by industrial chemicals.

The results can be odd.

Atlantic salmon that grow quickly thanks to a growth hormone gene from

another salmon species are deemed new animal drugs because the U.S. Food and Drug Administration decided to regulate genetically engineered animals under the Food, Drug and Cosmetic Act of 1938.

A cotton plant that makes insect-killing proteins with the help of a gene from a soil bacterium is a pesticide in the eyes of the U.S. Environmental Protection Agency, which regulates the crop under the Federal Insecticide, Fungicide and Rodenticide Act of 1972.

In what some critics deem the biggest contortion, many genetically modified crops are classified as potential plant pests so that the U.S. Department of Agriculture may preside over them through the Federal Plant Pest Act of 1957 even though the key traits added to the plants have nothing to do with pests.

See original here:
Food's genetic modification introduces brave new world of regulation

Recommendation and review posted by Bethany Smith